AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib ...

AstraZeneca Pharma India has surrendered marketing authorization for Olaparib (Lynparza) in India due to commercial reasons. The drug is indicated for metastatic castration-resistant prostate cancer.

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) for indication in combination with ...

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast cancer – the first drug in the class to show that in a clinical trial.

The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing.

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...